NASDAQ: PPBT
Purple Biotech Ltd Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their PPBT stock forecasts and price targets.

Forecast return on equity

Is PPBT forecast to generate an efficient return?

Company
-918.69%
Industry
140.91%
Market
90.47%
PPBT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PPBT forecast to generate an efficient return on assets?

Company
-842.66%
Industry
32.45%
PPBT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PPBT earnings per share forecast

What is PPBT's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.16
Avg 2 year Forecast
-$0.62
Avg 3 year Forecast
-$0.60

PPBT revenue forecast

What is PPBT's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$6.5M
Avg 2 year Forecast
$33.0M
Avg 3 year Forecast
$65.7M

PPBT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PPBT$2.45N/AN/A
KRRO$13.54$76.80+467.21%Strong Buy
BHST$7.20$13.00+80.56%Strong Buy
ASMB$16.85$31.00+83.98%Strong Buy
AGEN$4.70$15.50+229.79%Buy

Purple Biotech Stock Forecast FAQ

What is PPBT's earnings growth forecast for 2025-2027?

(NASDAQ: PPBT) Purple Biotech's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Purple Biotech's earnings in 2025 is $3,931,000.On average, 1 Wall Street analyst forecast PPBT's earnings for 2025 to be -$599,869,312, with the lowest PPBT earnings forecast at -$599,869,312, and the highest PPBT earnings forecast at -$599,869,312. On average, 1 Wall Street analyst forecast PPBT's earnings for 2026 to be -$320,619,805, with the lowest PPBT earnings forecast at -$320,619,805, and the highest PPBT earnings forecast at -$320,619,805.

In 2027, PPBT is forecast to generate -$310,277,230 in earnings, with the lowest earnings forecast at -$310,277,230 and the highest earnings forecast at -$310,277,230.

If you're new to stock investing, here's how to buy Purple Biotech stock.

What is PPBT's revenue growth forecast for 2028-2030?

(NASDAQ: PPBT) Purple Biotech's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Purple Biotech's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PPBT's revenue for 2028 to be $3,361,336,661, with the lowest PPBT revenue forecast at $3,361,336,661, and the highest PPBT revenue forecast at $3,361,336,661. On average, 1 Wall Street analysts forecast PPBT's revenue for 2029 to be $17,065,247,661, with the lowest PPBT revenue forecast at $17,065,247,661, and the highest PPBT revenue forecast at $17,065,247,661.

In 2030, PPBT is forecast to generate $33,975,356,707 in revenue, with the lowest revenue forecast at $33,975,356,707 and the highest revenue forecast at $33,975,356,707.

What is PPBT's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PPBT) forecast ROA is -842.66%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is PPBT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PPBT) Purple Biotech's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that PPBT's EPS will be -$1.16 for 2025, with the lowest EPS forecast at -$1.16, and the highest EPS forecast at -$1.16. On average, analysts forecast that PPBT's EPS will be -$0.62 for 2026, with the lowest EPS forecast at -$0.62, and the highest EPS forecast at -$0.62. In 2027, PPBT's EPS is forecast to hit -$0.60 (min: -$0.60, max: -$0.60).

What is PPBT's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PPBT) forecast ROE is -918.69%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.